Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
____________________________
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment
No. 2)*
____________________________
EDESA BIOTECH, INC.
(Name
of Issuer)
Common
Shares, no par value per share
(Title
of Class of Securities)
27966L108
(CUSIP
Number)
Kris Hanc
c/o
Bennett Jones LLP
3400 One First Canadian Place, P.O. Box 130, Toronto, ON, M5X
1A4
(416)
777-7395
(Name,
Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
January 8, 2020
(Date
of Event which Requires Filing of this Statement)
____________________________
If the
filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D,
and is filing this schedule because of §§
240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box. ☐
Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits.
See Rule 13d-7 for other parties to whom copies are to be
sent.
* The
remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a
prior cover page.
The
information required on the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 or otherwise subject to the
liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
SCHEDULE 13D
CUSIP No. 27966L108
|
|
Page 2
of 12
Pages
|
|||
|
|||||
1
|
NAME OF
REPORTING PERSON
10379085 Canada Inc.
|
||||
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)(a)
☐
(b)
☐
|
||||
3
|
SEC USE
ONLY
|
||||
4
|
SOURCE
OF FUNDS (see instructions)
OO
|
||||
5
|
CHECK
IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED ☐
PURSUANT TO ITEMS
2(d) or 2(e)
|
||||
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
||||
NUMBER OFSHARESBENEFICIALLYOWNED BYEACHREPORTINGPERSON
WITH
|
7
|
SOLE
VOTING POWER
0
|
|||
8
|
SHARED
VOTING POWER
690,843
(1)
|
||||
9
|
SOLE
DISPOSITIVE POWER
0
|
||||
10
|
SHARED
DISPOSITIVE POWER
690,843
(1)
|
||||
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
690,843
(1)
|
||||
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ☐
|
||||
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 11
7.8%
(Based on a total of 8,859,159 Common Shares of the Company
outstanding as of January 8, 2020)
|
||||
14
|
TYPE OF
REPORTING PERSON (see instructions)
CO
|
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
CUSIP No. 27966L108
|
|
Page 3
of 12
Pages
|
|||
|
|||||
1
|
NAME OF
REPORTING PERSON
PCRI Inc.
|
||||
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)(a)
☐
(b)
☐
|
||||
3
|
SEC USE
ONLY
|
||||
4
|
SOURCE
OF FUNDS (see instructions)
OO
|
||||
5
|
CHECK
IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED ☐
PURSUANT TO ITEMS
2(d) or 2(e)
|
||||
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
||||
NUMBER OFSHARESBENEFICIALLYOWNED BYEACHREPORTINGPERSON
WITH
|
7
|
SOLE
VOTING POWER
0
|
|||
8
|
SHARED
VOTING POWER
690,843
(1)
|
||||
9
|
SOLE
DISPOSITIVE POWER
0
|
||||
10
|
SHARED
DISPOSITIVE POWER
690,843
(1)
|
||||
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
690,843
(1)
|
||||
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ☐
|
||||
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 11
7.8%
(Based on a total of 8,859,159 Common Shares of the Company
outstanding as of January 8, 2020)
|
||||
14
|
TYPE OF
REPORTING PERSON (see instructions)
CO
|
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
CUSIP No. 27966L108
|
|
Page 4
of 12
Pages
|
|||
|
|||||
1
|
NAME OF
REPORTING PERSON
Morris Goodman
|
||||
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)(a)
☐
(b)
☐
|
||||
3
|
SEC USE
ONLY
|
||||
4
|
SOURCE
OF FUNDS (see instructions)
OO
|
||||
5
|
CHECK
IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED ☐
PURSUANT TO ITEMS
2(d) or 2(e)
|
||||
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
||||
NUMBER OFSHARESBENEFICIALLYOWNED BYEACHREPORTINGPERSON
WITH
|
7
|
SOLE
VOTING POWER
0
|
|||
8
|
SHARED
VOTING POWER
690,843
(1)
|
||||
9
|
SOLE
DISPOSITIVE POWER
0
|
||||
10
|
SHARED
DISPOSITIVE POWER
690,843
(1)
|
||||
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
690,843
(1)
|
||||
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ☐
|
||||
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 11
7.8%
(Based on a total of 8,859,159 Common Shares of the Company
outstanding as of January 8, 2020)
|
||||
14
|
TYPE OF
REPORTING PERSON (see instructions)
IN
|
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
CUSIP No. 27966L108
|
|
Page 5
of 12
Pages
|
|||
|
|||||
1
|
NAME OF
REPORTING PERSON
David Goodman
|
||||
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)(a)
☐
(b)
☐
|
||||
3
|
SEC USE
ONLY
|
||||
4
|
SOURCE
OF FUNDS (see instructions)
OO
|
||||
5
|
CHECK
IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED ☐
PURSUANT TO ITEMS
2(d) or 2(e)
|
||||
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
||||
NUMBER OFSHARESBENEFICIALLYOWNED BYEACHREPORTINGPERSON
WITH
|
7
|
SOLE
VOTING POWER
0
|
|||
8
|
SHARED
VOTING POWER
690,843
(1)
|
||||
9
|
SOLE
DISPOSITIVE POWER
0
|
||||
10
|
SHARED
DISPOSITIVE POWER
690,843
(1)
|
||||
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
690,843
(1)
|
||||
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ☐
|
||||
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 11
7.8%
(Based on a total of 8,859,159 Common Shares of the Company
outstanding as of January 8, 2020)
|
||||
14
|
TYPE OF
REPORTING PERSON (see instructions)
IN
|
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
CUSIP No. 27966L108
|
|
Page 6
of 12
Pages
|
|||
|
|||||
1
|
NAME OF
REPORTING PERSON
Gregory Orleski
|
||||
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)(a)
☐
(b)
☐
|
||||
3
|
SEC USE
ONLY
|
||||
4
|
SOURCE
OF FUNDS (see instructions)
OO
|
||||
5
|
CHECK
IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED ☐
PURSUANT TO ITEMS
2(d) or 2(e)
|
||||
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
||||
NUMBER OFSHARESBENEFICIALLYOWNED BYEACHREPORTINGPERSON
WITH
|
7
|
SOLE
VOTING POWER
0
|
|||
8
|
SHARED
VOTING POWER
690,843
(1)
|
||||
9
|
SOLE
DISPOSITIVE POWER
0
|
||||
10
|
SHARED
DISPOSITIVE POWER
690,843
(1)
|
||||
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
690,843
(1)
|
||||
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ☐
|
||||
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 11
7.8%
(Based on a total of 8,859,159 Common Shares of the Company
outstanding as of January 8, 2020)
|
||||
14
|
TYPE OF
REPORTING PERSON (see instructions)
IN
|
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
CUSIP No. 27966L108
|
|
Page 7
of 12 Pages
|
|||
|
|||||
1
|
NAME OF
REPORTING PERSON
Sonia Girolamo
|
||||
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)(a)
☐
(b)
☐
|
||||
3
|
SEC USE
ONLY
|
||||
4
|
SOURCE
OF FUNDS (see instructions)
OO
|
||||
5
|
CHECK
IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED ☐
PURSUANT TO ITEMS
2(d) or 2(e)
|
||||
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
||||
NUMBER OFSHARESBENEFICIALLYOWNED BYEACHREPORTINGPERSON
WITH
|
7
|
SOLE
VOTING POWER
0
|
|||
8
|
SHARED
VOTING POWER
690,843
(1)
|
||||
9
|
SOLE
DISPOSITIVE POWER
0
|
||||
10
|
SHARED
DISPOSITIVE POWER
690,843
(1)
|
||||
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
690,843
(1)
|
||||
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ☐
|
||||
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 11
7.8%
(Based on a total of 8,859,159 Common Shares of the Company
outstanding as of January 8, 2020)
|
||||
14
|
TYPE OF
REPORTING PERSON (see instructions)
IN
|
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
CUSIP No. 27966L108
|
|
Page 8
of 12
Pages
|
|||
|
|||||
1
|
NAME OF
REPORTING PERSON
Jean-Guy Goulet
|
||||
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)(a)
☐
(b)
☐
|
||||
3
|
SEC USE
ONLY
|
||||
4
|
SOURCE
OF FUNDS (see instructions)
OO
|
||||
5
|
CHECK
IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED ☐
PURSUANT TO ITEMS
2(d) or 2(e)
|
||||
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
Canada
|
||||
NUMBER OFSHARESBENEFICIALLYOWNED BYEACHREPORTINGPERSON
WITH
|
7
|
SOLE
VOTING POWER
0
|
|||
8
|
SHARED
VOTING POWER
690,843
(1)
|
||||
9
|
SOLE
DISPOSITIVE POWER
0
|
||||
10
|
SHARED
DISPOSITIVE POWER
690,843
(1)
|
||||
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
690,843
(1)
|
||||
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ☐
|
||||
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 11
7.8%
(Based on a total of 8,859,159 Common Shares of the Company
outstanding as of January 8, 2020)
|
||||
14
|
TYPE OF
REPORTING PERSON (see instructions)
IN
|
(1)
These shares are
owned directly by 10379085 Canada
Inc., which is a wholly owned subsidiary of PCRI
Inc.
This
Amendment No. 2 (“Amendment No. 2”) amends
and supplements the statement on Schedule 13D jointly filed by
(i)
10379085 Canada Inc., (ii) PCRI Inc, (iii) Morris Goodman, an
individual, (iv) David Goodman, an individual, (v) Gregory Orleski,
an individual, (vi) Sonia Girolamo, an individual, and (vii)
Jean-Guy Goulet, an individual (collectively, the “Reporting
Persons”) on June 25, 2019, as amended by Amendment
No. 1 filed by the Reporting Persons on September 10, 2019 (as so
amended and supplemented, the “Schedule 13D”), with
respect to the common shares, no par value per share (the
“Common Shares”) of Edesa Biotech, Inc., a British
Columbia corporation, formerly known as
“Stellar Biotechnologies, Inc.” (the
“Company” or the “Issuer”). Except as
expressly amended by this Amendment No. 2, the Schedule 13D
remains in full force and effect.
The
purpose of this Amendment No. 2 is to report an increase in
the Reporting Persons’ beneficial ownership of Common Shares
as a result of the purchase of Common Shares on January 8, 2020, as
described in this Amendment No. 2.
Item 1. Security and Issuer.
This
Schedule 13D relates to the Common Shares of the Company, which has
its principal executive offices at 100 Spy Court, Markham, Ontario,
Canada L3R 5H6.
Item 2. Identity and Background.
This Schedule 13D is
jointly filed by the Reporting Persons. 10379085 Canada
Inc. is a wholly owned subsidiary of PCRI Inc.
The principal address of
the Reporting Persons is 100-6111 vie.
Royalmount Ave., Montreal, Quebec, Canada, H4P
2T4.
Both 10379085 Canada
Inc. and PCRI are holding corporations. Morris Goodman, David
Goodman, Gregory Orleski and Sonia Girolamo are each officers and
directors of PCRI Inc. and 10379085 Canada Inc. and Jean-Guy
Goulet is a director of 10379085 Canada
Inc. The foregoing
individuals collectively make investment decisions with respect to
the securities held by 10379085 Canada
Inc.
During
the last five years, none of the Reporting Persons have been
convicted in a criminal proceeding (excluding traffic violations
and similar misdemeanors) or been a party to a civil proceeding of
a judicial or administrative body of competent jurisdiction and as
a result of such proceeding, was or is subject to a judgment,
decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state
securities laws or finding any violation with respect to such
laws.
Item 3. Source and Amount of Funds or Other
Consideration.
Item 3 is hereby supplemented as follows:
On January 6, 2020, the Company entered into a
Securities Purchase Agreement (the “Securities Purchase
Agreement”) with certain United States resident investors and
Subscription Agreements (the “Subscription Agreements”)
with certain non-U.S. investors, including 10379085 Canada
Inc., providing for the
issuance and sale by the Company of Common Shares in a registered
direct offering (the “Offering”). In a concurrent
private placement (the “Private Placement”), the
Company agreed to sell to such investors (i) Class A Purchase
Warrants to purchase 0.75 of a Common Share for each Common Share
purchased in the Offering (the “Class A Purchase
Warrants”) and (ii) Class B Purchase Warrants to purchase
0.50 of a Common Share for each Common Share purchased in the
offering (the “Class B Purchase Warrants,” and together
with the Class A Purchase Warrants, the “Purchase
Warrants”). 10379085 Canada
Inc. purchased 15,625 Common
Shares in the Offering at a purchase price of $3.20 and also
received 11,719 Class A Warrants and 7,813 Class B
Warrants.
The Class A Purchase Warrants will be
exercisable at any time on or after July 8, 2020 (the “Class
A Purchase Warrant Initial Exercise Date”), at an exercise
price of $4.80 per share and will expire on the third anniversary
of the Class A Purchase Warrant Initial Exercise Date. The Class B
Purchase Warrants will be exercisable at any time on or after July
8, 2020 (the “Class B Purchase Warrant Initial Exercise
Date”), at an exercise price of $4.00 per share and will
expire on the four month anniversary of the Class B Purchase
Warrant Initial Exercise Date. The exercise price and number of
Common Shares issuable upon the exercise of the Purchase Warrants
will be subject to adjustment in the event of any share dividends
and splits, reverse share split, recapitalization, reorganization
or similar transaction, as described in the Purchase
Warrants. None of the Common
Shares underlying the Purchase Warrants are included in the Common
Shares deemed to be beneficially owned by the Reporting
Persons<
/font> as
reported in this Amendment No. 2 as such Reporting Persons do not
have the right to acquire the shares within sixty days of the
filing date of this Amendment No. 2.
Item 4. Purpose of Transaction.
Reference is made
to the disclosure set forth under Item 3 of this Schedule 13D,
which disclosure is incorporated herein by reference.
The Reporting Persons acquired their securities in the Issuer for
investment purposes.
The Reporting Persons intend to review their investment in the
Issuer on a continuing basis and, depending on various factors,
including, without limitation, the Issuer’s financial
position, the price of the Common Shares, conditions in the
securities markets and general economic and industry conditions,
the Reporting Persons may, in the future, take such actions with
respect to their shares of the Issuer’s capital stock as they
deem appropriate, including, without limitation: purchasing
additional Common Shares; selling Common Shares; taking any action
to change the composition of the Issuer’s board of directors;
taking any other action with respect to the Issuer or any of its
securities in any manner permitted by law or changing their
intention with respect to any and all matters referred to in
paragraphs (a) through (j) below in this
Item 4.
Except as otherwise described in this Schedule, none of the
Reporting Persons currently has any plans or proposals that relate
to or would result in: (a) the acquisition by any person of
additional securities of the Issuer, or the disposition of
securities of the Issuer; (b) an extraordinary corporate
transaction, such as a merger, reorganization or liquidation,
involving the Issuer or any of its subsidiaries; (c) a sale or
transfer of a material amount of assets of the Issuer or any of its
subsidiaries; (d) any change in the present board of directors
or management of the Issuer, including any plans or proposals to
change the number or term of directors or to fill any existing
vacancies on the board; (e) any material change in the present
capitalization or dividend policy of the Issuer; (f) any other
material change in the Issuer’s business or corporate
structure; (g) any changes in the Issuer’s charter or
bylaws or other actions which may impede the acquisition of control
of the Issuer by any person; (h) causing a class of securities
of the Issuer to be delisted from a national securities exchange or
to cease to be authorized to be quoted in an interdealer quotation
system of a registered national securities association;
(i) causing a class of equity securities of the Issuer to
become eligible for termination of registration pursuant to
Section 12(g)(4) of the Securities Exchange Act of 1934, as
amended; or (j) any action similar to any of those enumerated
above.
Item 5. Interest in Securities of the Issuer.
(a)-(b)
Number of Common Shares beneficially owned:
|
|
|
10379085 Canada Inc.
|
|
690,843 shares
|
PCRI, Inc.
|
|
690,843 shares
|
Morris Goodman
|
|
690,843 shares
|
David Goodman
|
|
690,843 shares
|
Gregory Orleski
|
|
690,843 shares
|
Sonia Girolamo
|
|
690,843 shares
|
Jean-Guy Goulet
|
|
690,843 shares
|
Percent of class:
|
|
|
10379085 Canada Inc.
|
|
7.8%
|
PCRI, Inc.
|
|
7.8%
|
Morris Goodman
|
|
7.8%
|
David Goodman
|
|
7.8%
|
Gregory Orleski
|
|
7.8%
|
Sonia Girolamo
|
|
7.8%
|
Jean-Guy Goulet
|
|
7.8%
|
The percentage ownership was calculated based on a total of 8,859,159 Common Shares of
the Company outstanding as of January 8, 2020.
Number of shares as to which such person has:
(i)
Sole power to vote or to direct the vote:
|
10379085 Canada
Inc.
|
|
0 shares
|
PCRI,
Inc.
|
|
0 shares
|
Morris
Goodman
|
|
0 shares
|
David
Goodman
|
|
0 shares
|
Gregory
Orleski
|
|
0 shares
|
Sonia
Girolamo
|
|
0 shares
|
Jean-Guy
Goulet
|
|
0 shares
|
(ii)
|
Shared power to vote or to direct the vote:
|
|
|
|
10379085 Canada Inc.
|
|
690,843 shares
|
PCRI, Inc.
|
|
690,843 shares
|
Morris Goodman
|
|
690,843 shares
|
David Goodman
|
|
690,843 shares
|
Gregory Orleski
|
|
690,843 shares
|
Sonia Girolamo
|
|
690,843 shares
|
Jean-Guy Goulet
|
|
690,843 shares
|
(iii)
Sole
power to dispose or to direct the disposition of:
|
|
|
|
10379085 Canada Inc.
|
|
0 shares
|
PCRI, Inc.
|
|
0 shares
|
Morris Goodman
|
|
0 shares
|
David Goodman
|
|
0 shares
|
Gregory Orleski
|
|
0 shares
|
Sonia Girolamo
|
|
0 shares
|
Jean-Guy Goulet
|
|
0 shares
|
(iv)
Shared power to dispose or to direct the disposition of:
|
10379085 Canada
Inc.
|
|
690,843 shares
|
PCRI,
Inc.
|
|
690,843 shares
|
Morris
Goodman
|
|
690,843 shares
|
David
Goodman
|
|
690,843 shares
|
Gregory
Orleski
|
|
690,843 shares
|
Sonia
Girolamo
|
|
690,843 shares
|
Jean-Guy
Goulet
|
|
690,843 shares
|
(d)-(e) Not applicable.
Item
6.
Contracts,
Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer.
This
Amendment No. 2 does not amend the information previously provided
in response to this Item 6.
Item 7. Material to be Filed as Exhibits.
This
Amendment No. 2 does not amend the information previously provided
in response to this Item 7.
SCHEDULE 13D
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true,
complete and correct.
|
10379085 Canada Inc. |
|
|
|
|
|
|
Date: January 22,
2020
|
By:
|
/s/ Gregory
Orleski
|
|
|
|
Gregory Orleski
|
|
|
|
|
|
|
PCRI Inc. |
|
|
|
|
|
|
|
By:
|
/s/ Gregory Orleski
|
|
|
|
Gregory Orleski
|
|
|
|
|
|
|
By:
|
/s/ Morris Goodman |
|
|
|
Morris Goodman |
|
|
|
|
|
|
By:
|
/s/ David Goodman |
|
|
|
David Goodman |
|
|
|
|
|
|
By:
|
/s/ Gregory Orleski |
|
|
|
Gregory Orleski |
|
|
|
|
|
|
By:
|
/s/ Sonia Girolamo |
|
|
|
Sonia Girolamo |
|
|
|
|
|
|
By:
|
/s/ Jean-Guy Goulet |
|
|
|
Jean-Guy Goulet |
|